General Information of Drug (ID: DMEZ0H5)

Drug Name
LY2963016 Drug Info
Indication
Disease Entry ICD 11 Status REF
Type-1/2 diabetes 5A10-5A11 Phase 3 [1]
Cross-matching ID
TTD Drug ID
DMEZ0H5

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting Insulin (INS)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Inulin DM1Y2JH Measure kidney function MG02 Approved [3]
Insulin Zinc Susp Recombinant Human DM6MO9X Diabetic complication 5A2Y Approved [3]
Insulin-glargine DMR4HIW Diabetic complication 5A2Y Approved [3]
Insulin Susp Isophane Recombinant Human DMW8KI7 Diabetic complication 5A2Y Approved [3]
Insulin determir DM79NZ5 Diabetic complication 5A2Y Approved [4]
Insulin Susp Protamine Zinc Beef/Pork DM0NATE Diabetic complication 5A2Y Approved [3]
Insulin-aspart DMX7V28 Diabetic complication 5A2Y Approved [3]
Insulin degludec DMPL395 Type-1/2 diabetes 5A10-5A11 Approved [5]
Insulin-detemir DMOA4VW Type-1/2 diabetes 5A10-5A11 Approved [3]
SAR342434 DMR0EWV Diabetic complication 5A2Y Phase 3 [6]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Insulin (INS) TTZOPHG INS_HUMAN Agonist [2]

References

1 ClinicalTrials.gov (NCT02302716) A Study of LY2963016 Compared to LANTUS in Adult Participants With Type 2 Diabetes Mellitus. U.S. National Institutes of Health.
2 Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus ) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study. Diabetes Obes Metab.2015 Aug;17(8):726-33.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 2005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006).
5 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
6 Biosimilar insulins: a European perspective. Diabetes Obes Metab. 2015 May; 17(5): 445-451.